Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Frank Marino

Family Medicine Sioux City, IA Doctor of Osteopathy

NPI 1699740159 CMS profile 212619

2600 Outer Dr N, Sioux City, IA 51104

Open in the dashboard

General payments

$8,030

577 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frank Marino of Sioux City, IA is reported in the CMS Open Payments database as having received $8,030 across 577 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Family Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $798 41
2024 General $1,831 135
2023 General $1,157 76
2022 General $1,066 74
2021 General $1,162 89
2020 General $747 55
2019 General $1,270 107

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frank Marino
  • Family Medicine median
  • Middle half of Family Medicine
  • National median

In program year 2025, general payments to Frank Marino were reported at $798. Among 56,786 Family Medicine profiles paid that year, the median was $155 and the middle half received between $45 and $549.

Show as a table
Year Frank Marino Family Medicine median Middle half National median
2019 $1,270 $150 $41–$543 $163
2020 $747 $120 $32–$415 $114
2021 $1,162 $137 $35–$551 $132
2022 $1,066 $137 $37–$512 $149
2023 $1,157 $149 $42–$545 $160
2024 $1,831 $156 $44–$560 $164
2025 $798 $155 $45–$549 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $1,121 82 payments
  2. Amgen Inc. $889 73 payments
  3. AstraZeneca Pharmaceuticals LP $680 39 payments
  4. Pfizer Inc. $568 43 payments
  5. Lilly USA, LLC $514 56 payments
  6. Merck Sharp & Dohme Corporation $416 24 payments
  7. Amarin Pharma Inc. $325 23 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $299 23 payments
  9. Astellas Pharma US Inc $279 18 payments
  10. AbbVie, Inc. $263 15 payments
  11. Other $2,677 181 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,991 573 payments
  2. Education $40 4 payments
Products named General payments · program years 2019–2025
  1. Ozempic $835 62 payments
  2. RYBELSUS $711 53 payments
  3. Prolia $506 38 payments
  4. EVENITY $469 35 payments
  5. ELIQUIS $460 31 payments
  6. Repatha $389 35 payments
  7. Vascepa $325 23 payments
  8. FARXIGA $287 15 payments
  9. Otezla $263 25 payments
  10. Kerendia $258 15 payments
  11. Other $7,284 525 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 143 drugs

Part D claims

8,681

Median for Family Practice: 1,826

Drug cost

$476,148

Median for Family Practice: $120,094

Branded share of claims

18.2%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 137 $90,350
Ozempic Semaglutide Brand 67 $75,347
Farxiga Dapagliflozin Propanediol Brand 63 $51,844
Mounjaro Tirzepatide Brand 29 $36,686
Breo Ellipta Fluticasone/Vilanterol Brand 58 $30,248
Januvia Sitagliptin Phosphate Brand 23 $23,858
Jardiance Empagliflozin Brand 24 $23,765
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 28 $23,331
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 14 $18,431
Novolog Flexpen Insulin Aspart Brand 16 $5,821

The 10 drugs with the highest cost, of 143 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 106 billing codes

Paid by Medicare

$193,561

Of which drugs: $60,973

Medicare patients

363

Average age 73

Services billed

14,620

199 women, 164 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 73%
Arthritis 34%
Diabetes 25%
COPD 24%
Chronic kidney disease 20%
Osteoporosis 20%
Ischemic heart disease 18%
Depression 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 15 1,560 $31,646
Vaccine for influenza for injection into muscle 90662 Office 80 84 $6,823
Pcv20 vaccine im 90677 Office 13 13 $3,779
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 36 616 $414

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 32 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
ELIQUIS
  • PFIZER INC. $112
  • E.R. Squibb & Sons, L.L.C. $18
$130 137 —
Veozah
  • Astellas Pharma US Inc $113
$113 — —
JARDIANCE
  • Lilly USA, LLC $96
$96 24 —
MOUNJARO
  • Lilly USA, LLC $95
$95 29 —
RYBELSUS
  • Novo Nordisk Inc $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 32 with Patron

Records

577 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Family Medicine in Iowa

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record